Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160339 | 0.84 | HCRTR2 (0.32) | HCRTR2HRH3CMA1SMN1; SMN2KMT2A | |
| SCHEMBL5158933 | 0.83 | HRH3 (0.33) | HCRTR2HRH3USP2CMA1SMN1; SMN2 | |
| SCHEMBL5163678 | 0.80 | ALOX5AP (0.36) | USP2SMN1; SMN2KMT2APOLB | |
| SCHEMBL5159931 | 0.77 | RAB9A (0.37) | USP2SMN1; SMN2KMT2APOLB | |
| SCHEMBL5160346 | 0.74 | MEN1 (0.33) | KMT2A | |
| SCHEMBL5160904 | 0.71 | SMN1; SMN2 (0.34) | CMA1SMN1; SMN2KMT2APOLB | |
| SCHEMBL6179708 | 0.70 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2APOLB | |
| SCHEMBL5161578 | 0.70 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2APOLB | |
| SCHEMBL5417520 | 0.70 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2A | |
| SCHEMBL5160884 | 0.68 | HRH3 (0.32) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | HCRTR2 4475/4885HRH3 468/4885USP2 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.